



Content highlights

Release date

December 2024

Updated throughout the year to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, EU5, Japan

Primary research

19 country-specific interviews with thought-leading endocrinologists and diabetologists

Supported by survey data collected for this and other Clarivate research

Epidemiology

Prevalence of T2D by country with population-specific diagnosed and drug-treated rates

Forecast

10-year, annualized, drug-level sales and patient share of key T2D therapies through 2033, segmented by brands / generics

Drug treatments

Coverage of key current and emerging therapies

Type 2 Diabetes

Spotlight on Disease Landscape & Forecast

Market outlook

The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity of several key T2D brands such as the dipeptidyl peptidase-IV (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists will exert downward pressure on market sales. Nonetheless, the launch and uptake of Eli Lilly's first-in-class, glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist, Mounjaro, and other late-phase therapies will support the T2D market through 2033. Significant unmet need remains for disease-modifying therapies that can offer a better quality of life and reduce the treatment burden of intensive combination therapy.

Questions answered

- What are the drivers and constraints in the T2D market, and how will the market evolve over the forecast period?
- How has the launch of Eli Lilly's tirzepatide (Mounjaro) affected the prescribing of GLP-1 receptor agonists such as Eli Lilly's Trulicity and Novo Nordisk's Ozempic in the United States and Japan? How will the therapy be received in the European markets?
- How will the launch of nonbranded therapies affect the G7 T2D market?
- What do key opinion leaders think about emerging therapies such as Novo Nordisk's insulin icodec and CagriSema?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Learn more about Clarivate's full suite of type 2 diabetes solutions:

healthcare.support@clarivate.com | clarivate.com

© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.